Outreach and Connection to Care for Chronic Kidney Disease in a Workplace Wellness Setting: A Cost-Effectiveness Analysis

被引:0
|
作者
Li, Yonghong [1 ]
Devlin, James J. [1 ]
机构
[1] Quest Diagnost, 33608 Ortega Highway, San Juan Capistrano, CA 92675 USA
关键词
chronic kidney disease; cost-effectiveness analysis; Markov modeling; CARDIOVASCULAR OUTCOMES; NEPHROPATHY; INHIBITORS;
D O I
10.1089/pop.2019.0206
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Because chronic kidney disease (CKD) is underdiagnosed, many patients do not receive care that could slow or prevent progression. Potential CKD patients can be identified during employee wellness events and referred into care by a CKD outreach program. This study assessed the health and economic benefits associated with a CKD outreach program. A model-based cost-effectiveness analysis was conducted for a cohort of patients at risk for CKD under 2 scenarios: wellness events with a CKD outreach program and wellness events without outreach. The outreach program identified potential CKD patients based on estimated glomerular filtration rates. Health outcomes and total cost to payers were estimated with Markov models using 1-year cycles. Because outreach could be offered to either patients with diabetes or to all potential CKD patients, these groups were modeled separately. The authors assumed 40% percent of potential CKD patients accepted the invitation to participate in the CKD outreach program. Model parameters were taken from peer-reviewed literature. The study was conducted from the perspective of self-insured employers over a 5-year time horizon. The study found that the CKD outreach program resulted in a gain of 2.3 quality-adjusted life-years and saved $500,211 when 1000 potential CKD patients with diabetes were invited. When potential CKD patients were invited without regard for diabetes status, 0.8 quality-adjusted life-years were gained at a cost savings of $34,161. The authors concluded that CKD outreach programs can improve health outcomes for patients with CKD and save costs for payers.
引用
收藏
页码:487 / 494
页数:8
相关论文
共 50 条
  • [21] Cost-effectiveness of chronic kidney disease mass screening test in Japan
    Kondo, Masahide
    Yamagata, Kunihiro
    Hoshi, Shu-Ling
    Saito, Chie
    Asahi, Koichi
    Moriyama, Toshiki
    Tsuruya, Kazuhiko
    Yoshida, Hideaki
    Iseki, Kunitoshi
    Watanabe, Tsuyoshi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (02) : 279 - 291
  • [22] Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
    Tisdale, Rebecca L.
    Cusick, Marika M.
    Aluri, Kelly Zhang
    Handley, Thomas J.
    Joyner, Alice Kate Cummings
    Salomon, Joshua A.
    Chertow, Glenn M.
    Goldhaber-Fiebert, Jeremy D.
    Owens, Douglas K.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (13) : 3380 - 3387
  • [23] Workplace Outreach Program Improves Management of Chronic Kidney Disease
    Iakoubova, Olga A.
    Tong, Carmen H.
    Rowland, Charles M.
    Arellano, Andre R.
    Bare, Lance A.
    Fragala, Maren S.
    Birse, Charles E.
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2022, 64 (06) : 482 - 487
  • [24] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE (CKD) MANAGEMENT IN THE UK
    Ramos, M.
    Gerlier, L.
    Uster, A.
    Aguirre, A. R.
    Muttram, L.
    Frankel, A. H.
    Lamotte, M.
    VALUE IN HEALTH, 2023, 26 (12) : S131 - S132
  • [25] Cost-effectiveness of chronic kidney disease mass screening test in Japan
    Masahide Kondo
    Kunihiro Yamagata
    Shu-Ling Hoshi
    Chie Saito
    Koichi Asahi
    Toshiki Moriyama
    Kazuhiko Tsuruya
    Hideaki Yoshida
    Kunitoshi Iseki
    Tsuyoshi Watanabe
    Clinical and Experimental Nephrology, 2012, 16 : 279 - 291
  • [26] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE NETHERLANDS
    Fens, T.
    Weersma, M.
    Postma, M. J.
    Boersma, C.
    de Jong, L.
    VALUE IN HEALTH, 2023, 26 (12) : S132 - S132
  • [27] THE COST-EFFECTIVENESS OF SCREENING FOR MICROALBUMINURIA: A SIMULATION MODEL FOR CHRONIC KIDNEY DISEASE
    Hoerger, Thomas
    Witterborn, John
    Segel, Joel
    Burrows, Nilka Rios
    Eggers, Paul
    Pavkov, Meda
    Jordan, Regina
    Schoolwerth, Anton C.
    Willams, Desmond
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A42 - A42
  • [28] Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
    Schlackow, Iryna
    Kent, Seamus
    Herrington, William
    Emberson, Jonathan
    Haynes, Richard
    Reith, Christina
    Collins, Rory
    Landray, Martin J.
    Gray, Alastair
    Baigent, Colin
    Mihaylova, Borislava
    Baxter, A.
    Young, A.
    Hill, M.
    Knott, C.
    Cass, A.
    Feldt-Rasmussen, B.
    Fellstrom, B.
    Grobbee, D. E.
    Gronhagen-Riska, C.
    Haas, M.
    Holdaas, H.
    Hooi, L. S.
    Jiang, L.
    Kasiske, B.
    Krairittichai, U.
    Levin, A.
    Massy, Z. A.
    Tesar, V.
    Walker, R.
    Wanner, C.
    Wheeler, D. C.
    Wiecek, A.
    Dasgupta, T.
    Herrington, W.
    Lewis, D.
    Mafham, M.
    Majoni, W.
    Reith, C.
    Emberson, J.
    Parish, S.
    Simpson, D.
    Strony, J.
    Musliner, T.
    Agodoa, L.
    Armitage, J.
    Chen, Z.
    Craig, J.
    de Zeeuw, D.
    Gaziano, J. M.
    KIDNEY INTERNATIONAL, 2019, 96 (01) : 170 - 179
  • [29] Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
    Rebecca L. Tisdale
    Marika M. Cusick
    Kelly Zhang Aluri
    Thomas J. Handley
    Alice Kate Cummings Joyner
    Joshua A. Salomon
    Glenn M. Chertow
    Jeremy D. Goldhaber-Fiebert
    Douglas K. Owens
    Journal of General Internal Medicine, 2022, 37 : 3380 - 3387
  • [30] Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait
    Swidan, Ahmed
    Elsisi, Gihan Hamdy
    Ibrahim, Mohamed M. M.
    Aljazzar, Mohammad
    Sallam, Hossameldin Tawfik
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 271 - 282